We conducted a nationwide retrospective study to evaluate the prognostic influence of +1, der(1;7)(q10;p10) [hereafter der (1;7)] and −7/del(7q) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for de novo myelodysplastic syndromes (MDS). In this database, 69 MDS patients with der(1;7), 75 with −7/del(7q), and 511 with normal karyotype (NK) underwent allo-HSCT at advanced disease status. The 3-year overall survival (OS) and cumulative incidence of relapse (CIR) were 50.4 and 19.4% for those with der(1;7), 36.2 and 38.4% for −7/del(7q), and 51.1 and 20.7% for NK, respectively. In the multivariate analysis, the presence of −7/del(7q) correlated with a significantly shorter OS (HR [95% CI], 1.38 [1.00-1.89]; P = 0.048) and higher CIR (HR, 2.11 [1.36-3.28]; P = 0.001) than those with NK. There were 23 patients with der(1;7), 29 with −7/del(7q), and 347 with NK who underwent allo-HSCT at early disease status. The 3-year OS and CIR were as follows: 47.3 and 9.5% for the der(1;7) group, 70.5 and 13.8% for −7/del(7q), and 70.9 and 5.6% for NK, respectively. No significant differences were observed in OS and CIR among three groups. The impact of the loss of chromosome 7q on OS and CIR may differ based on its type and disease status after allo-HSCT for MDS.
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Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem-cell disorders, which are characterized by ineffective hematopoiesis with one or more lineages of cytopenias [1] . Acquired cytogenetic abnormalities at the time of diagnosis are one of the major and independent prognostic factors in outcome predictions for MDS. In the International Prognostic Scoring System (IPSS) [2] , abnormalities on chromosome 7 have been categorized as a poor-risk karyotype. Chromosome 7 abnormality comprises various patterns including monosomy 7, the partial deletion of 7q [del(7q)], and unbalanced translocations der(1;7)(q10; p10). In the revised IPSS [3] , abnormalities on chromosome 7 have been subdivided into three groups (i.e. monosomy 7, del(7q), or any others), suggesting that the impact of the loss of 7q on the prognosis of MDS may differ depending on its pattern. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative therapeutic option for MDS patients, but is associated with severe toxicity [4] [5] [6] ; therefore, estimations of the outcomes of patients after allo-HSCT are crucial for establishing therapeutic strategies. Among several prognostic scoring systems, cytogenetic abnormalities are the most significant indicator of posttransplant outcomes [7] [8] [9] [10] .
The International System for Human Cytogenetic Nomenclature (2005) described that 46,XY (or 46,XX), +1, der(1;7)(q10;p10) [hereafter der(1;7)] was characterized by an allelic imbalance in trisomy 1q and monosomy 7q [11] . Thus, der(1;7) is currently considered to be a "karyotypic variant" of monosomy 7 or del(7q) [hereafter −7/del(7q)]. Previous studies showed that patients with der(1;7) had different clinical and pathological features [12] [13] [14] [15] ; compared with those with −7/de(7q), patients having der(1;7) were older at diagnosis, their hemoglobin levels, platelet counts, and blast counts were lower. However, it was controversial whether the prognosis was different between der(1;7) and −7/del(7q) groups; the median overall survival time after their diagnosis were 1.1-1.9 and 0.8-2.7 years in MDS patients having der(1;7) and −7/del(7q), respectively [12] [13] [14] [15] [16] . In addition, due to the small number of patients who received allo-HSCT in these studies, the prognostic impact of the different types of the loss of 7q on posttransplant outcomes was not fully evaluated.
In order to more clearly estimate the post-transplant outcomes of MDS with the loss of 7q, we performed a retrospective analysis on patients with der(1;7) or −7/del (7q) who were treated with allo-HSCT using the Transplant Registry Unified Management Program (TRUMP) database.
Patients and methods

Date collection
Data on adult patients (aged 16 years or older) with de novo MDS who underwent their first allo-HSCT between January 1 1999 and December 31 2012 were collected by the Japan Society for Hematopoietic Cell Transplantation (JSHCT) and the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT) using TRUMP [17] [18] [19] . Data on these patients were collected and updated as of December 31 2013. This study was approved by the TRUMP Committee (approval no. 8-7), and by the Ethics Committee of Nagasaki University Hospital (approval no. 12052896) at which this study was organized.
Patient selection
The original dataset consisted of 4577 adults who were diagnosed with MDS according to the French-AmericanBritish (FAB) classification [20] . The patients included in the present study had a cytogenetic report at diagnosis which identified der(1;7) or −7/del(7q) as the sole clonal cytogenetic abnormality (at least two cells with an identical rearrangement). Patients with chronic myelomonocytic leukemia or secondary-and therapy-related MDS were excluded from this study. Data on 1054 patients with MDS were collected from this dataset: 92 and 104 patients with der(1;7) and −7/del(7q) as the sole cytogenetic abnormality, respectively; 858 patients with normal karyotype (NK), who were included in this study as a reference group.
Study end-points and definitions
The primary outcome studied was survival. Patients were considered to have an event at the time of death from any cause; survivors were censored at the last follow-up.
Relapse was defined as disease recurrence, and transplantation-related mortality (TRM) was considered to be a competing event in the present study. TRM was defined as death without evidence of disease recurrence after allo-HSCT.
The following karyotypic descriptions were regarded as der(1;7)(q10;p10), as previously reported [12] : der(1;7) (q10;p10); der(1)t(1;7)(p11;p11); +t(1;7)(p11;p11),−7; der (1;7)(p10;q10); and dic(1;7)(p11;q11).
Data collected for the analysis included clinical characteristics, such as age at allo-HSCT, gender, disease subtype according the FAB classification at diagnosis [20] , IPSS at diagnosis, bone marrow blast percent at transplantation, the year of allo-HSCT, time from MDS diagnosis to transplantation, performance status (PS) according to the Eastern Cooperative Oncology Group criteria at transplantation, type of donor source, ABO matching between the recipient and donor, date alive at the last follow-up, and date and cause of death. Conditioning regimens were classified as myeloablative, reduced-intensity, and nonmyeloablative conditioning according to the established criteria [21, 22] . GVHD prophylaxis was a cyclosporine-or tacrolimus-based regimen. HLA-A, -B, and -DRB1 were identified by serological or molecular typing in related donors using molecular typing in unrelated bone marrow donors and serological typing in unrelated cord blood donors [23, 24] . To reflect current practices in Japan, the number of HLA mismatches was assessed with respect to serological data in related and unrelated cord blood donors, and by allele data in unrelated bone marrow donors. Due to missing data on IPSS components at allo-HSCT in TRUMP, the disease risk was stratified according to the FAB classification as previously reported [25, 26] ; early disease status contained those who had stayed refractory anemia (RA) or RA with ring sideroblasts (RARS) until allo-HSCT. Patients who were diagnosed as RA with excess blasts (RAEB) or RAEB in transformation (RAEB-t) at any time before allo-HSCT were categorized as in advanced disease status.
Statistical analysis
Continuous variables were compared using the Wilcoxon rank-sum test or Kruskal-Wallis test. Categorical variables were compared between groups using the chi-squared test. The probabilities of OS were estimated by the KaplanMeier method and group comparisons were performed by the log-rank test. Cumulative incidence of relapse (CIR) and TRM were estimated in a competing risk setting, and group comparisons were performed by the Gray test. Regarding relapse, death before relapse was the competing event; and for TRM, death after relapse was the competing event [27, 28] . In order to assess variables potentially affecting post-transplant outcomes, OS was evaluated using Cox's proportional hazards regression models, whereas the probabilities of relapse and TRM were evaluated using the Fine and Gray proportional hazards model for the subdistribution of competing risks [28] .
Factors associated with at least borderline significance (P ≤ 0.10) in the univariate analysis and cytogenetic groups were subjected to a multivariate analysis using a backward stepwise covariate selection. Potential interactions between covariates were also examined. Effect estimates were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). All P-values were two-tailed, and Pvalues ≤ 0.05 were considered to be significant. All statistical analyses were performed using Stata software, version 12 (Stata, College Station, Tx, USA.), and graphical presentations were performed using EZR software, version 1.24 (Saitama Medical Center, Jichi Medical University) [29] .
Results
Patient characteristics
In our entire cohort, der(1;7) group was likely to be older than −7/del(7q) and NK groups (P < 0.001); median age were 55.5 years (range, 18-70 years) in der(1;7) group; 52.5 years (range, 16-73 years) in −7/del(7q) group; 50.0 years (range, 16-73 years) in NK group. Male predominance was noted in both der(1;7) and −7/del(7q) groups: male were 78 out of 94 (84.8%) in der(1;7) group; 72 out of 104 (69.2%) in −7/del(7q) group; 519 out of 858 (60.5%) in NK group. This tendency was also evident in der (1;7) group compared to −7/del(7q) group (P = 0.012).
As demonstrated in previous studies, MDS patients with der(1;7) were more likely to show a lower percentage of myeloblasts and slower disease progression than those with −7/del(7q) [12, 13] . In order to estimate the prognostic value of der(1;7) and -7/del(7q) in detail, we analyzed posttransplant outcomes by the disease status, and patients were divided into two groups; 655 (62.1%) at advanced status, and 399 (37.9%) at early disease status at transplantation. The demographic and baseline characteristics of patients are shown in Table 1 .
Transplantation outcomes by disease-risk stratification
In the entire cohort, the 3-year probability of OS after allo-HSCT was 57.2% (95% CI 53.9-60.3); the 3-year CIR and TRM were 16.3% (95% CI 14.0-18.7%) and 27.0% (95% CI 24.3-29.9%), respectively. The univariate analysis demonstrated that patients with advanced disease status showed a worse OS (P < .001) and increased CIR (P < .001) than those with early disease status (Supplemental Fig. 1A , B). However, no significant difference was observed in TRM by the disease status (Supplemental Fig. 1C ). Among the patients with both advanced and early disease status, no significant difference was observed for the cumulative incidences of neutrophil engraftment, acute-, and chronic-GVHD by each cytogenetic group (data not shown).
OS by the cytogenetic group in patients with advanced disease status Among those with advanced disease status at allo-HSCT, 69, 75, and 511 patients had der(1;7), −7/del(7q), and NK, respectively (Supplemental Table 1 ).
The 3-year probabilities of OS after allo-HSCT were 50.4% (95% CI 37.4-62.0%), 36.2% (95% CI 24.7-47.8%), and 51.1% (95% CI 46.4-55.7%) in der(1;7), −7/del(7q), and NK groups, respectively (Fig. 1a) . In the univariate analysis using the log-rank test, OS was significantly shorter in −7/del(7q) group than in NK group (P = 0.011), whereas no significant difference was noted in OS between der(1;7) and NK groups (P = 0.780). In the multivariate analysis, −7/del(7q) group was a significantly worse factor than NK group (HR 1.38, 95% CI 1.00-1.89, P = 0.048), while der (1;7) group was not (HR 0.90, 95% CI 0.62-1.31, P = .583) ( Table 2 ). There was no interaction modification between the cytogenetic group and other covariates. Four factors other than the cytogenetic group correlated with worse OS: recipient age (≥60 years, HR 1.39, 95% CI 1.05-1.85, P = 0.023), PS at transplantation (PS 1-4, HR 1.56, 95% CI 1.22-1.99, P < 0.001; missing data on PS, HR 1.87, 95% CI 1.26-2.77, P = 0.002), the type of donor source (unrelated cord blood, HR 1.85, 95% CI 1.33-2.56, P < 0.001), and the interval from diagnosis to transplantation (>7.8 months, HR 1.54, 95% CI 1.22-1.95, P < 0.001) (Supplemental Table 2 ).
CIR and TRM by the cytogenetic group in patients with advanced disease status
The 3-year CIR were 19.4% (95% CI 10.5-30.3%), 38.4% (95% CI 26.9-49.7%), and 20.7% (95% CI 17.1-24.5%) for der(1;7), −7/del(7q), and NK groups, respectively (Fig. 1b) . The univariate analysis using Gray test showed that the CIR was significantly higher for −7/del(7q) group than for NK group (P < 0.001), whereas no significant difference was noted between der(1;7) and NK groups (P = 0.816). Furthermore, −7/del(7q) group was likely to show a higher CIR than der(1;7) group in the Kaplan-Meier analysis (P = 0.015). The multivariate analysis demonstrated that CIR was significantly higher in −7/del(7q) group than in NK group (HR 2.11, 95% CI 1.36-3.280, P = 0.001) (see Table 2 ). There was no interaction modification between the cytogenetic group and other covariates. In the univariate and multivariate analyses, three factors were significant: PS at transplantation (PS 1-4, HR 2.32, 95% CI 1.38-3.90, P = 0.002), the use of antithymocyte globulin (ATG) during conditioning (presence, HR 2.42, 95% CI 1.29-4.57, P = 0.006), and the type of donor source (unrelated bone marrow, HR 0.57, 95% CI 0.34-0.94, P = 0.028; unrelated cord Table 2 ). For the comparison between −7/del(7q) and der(1;7) groups, the higher CIR among −7/del(7q) group was maintained in the multivariate analysis (HR 2.19, 95% CI 1.08-4.44, P = 0.029) (supplemental Table 3 ). The 3-year TRM were 31.1% (95% CI 20.0-42.7%), 27.1% (95% CI 17.0-38.1%), and 29.1% (95% CI 25.0-33.3%) in the der(1;7), −7/del(7q), and NK groups, respectively (Fig. 1c) . The univariate and multivariate analyses did not identify the cytogenetic group as a significant factor for TRM. However, in the multivariate analysis, four factors correlated with higher TRM: recipient age at transplantation (≥60 year, HR 1.46, 95% CI 1.00-2.11, P = 0.045), the type of donor source (unrelated bone marrow, HR 1.72, 95% CI 1.11-2.66, P = 0.016; HLAmismatched related graft, HR 3.02, 95% CI 1.73-5.24, P < 0.001; unrelated cord blood, HR 2.25, 95% CI 1.35-3.74, P = 0.002), the interval from diagnosis to transplantation (>7. 
OS by the cytogenetic group in patients with early disease status
Among patients with early disease status at transplantation, 23, 29, and 347 showed der(1;7), −7/del(7q), and NK, respectively (Supplemental Table 5 ).
The 3-year probabilities of OS after allo-HSCT were 47.3% (95% CI 21.5-69.5%), 70.5% (95% CI 49.3-84.1%), and 70.9% (95% CI 65.6-75.5%) in der(1;7), −7/del(7q), and NK groups, respectively (Fig. 2a) . The univariate and multivariate analyses revealed no significant differences in OS among the three groups (Table 3 ). There was no interaction modification between the cytogenetic group and Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes. . .other covariates. In the multivariate analysis, recipient age at transplantation (≥60 years, HR 2.21, 95% CI 1.42-3.44, P < 0.001), the type of donor source (unrelated cord blood, HR 1.77, 95% CI 1.03-3.04, P = 0.037), and the type of disease-altering therapy prior to allo-HSCT (intensive chemotherapy, HR 2.10, 95% CI 1.15-3.84, P = 0.016) correlated with shorter OS (Supplemental Table 6 ).
Relapse and TRM by the cytogenetic group in patients with early disease status
The 3-year CIR were 9.5% (95% CI 1.5-26.8%), 13.8% (95% CI 4.2-29.0%), and 5.6% (95% CI 3.5-8.4%) in der (1;7), −7/del(7q), and NK groups, respectively (Fig. 2b) . In terms of the cytogenetic group, the univariate and multivariate analyses showed no significant differences in CIR among three groups (see Table 3 ). Four factors other than the cytogenetic group correlated with a higher CIR: recipient age at transplantation (50-59 years, HR 3.08, 95% CI 1.05-9.10, P = 0.041), the intensity of the conditioning regimen (non-myeloablative conditioning regimen, HR 11.01, 95% CI 2.55-47. Table 4 ). The 3-year TRM were 42.8% (95% CI 17.0-66.7%), 18.3% (95% CI 7.7-32.7%), and 23.3% (95% CI 18.8-28.0%) in der(1;7), −7/del(7q), and NK groups, respectively, without a significant difference (Fig. 2c) . The multivariate analysis demonstrated that the type of donor source (HLA-mismatched related graft, HR 2.44, 95% CI 1.01-5.88, P = 0.047; unrelated cord blood, HR 2.55, 95% CI 1.34-4.83, P = 0.004) and type of disease-altering therapy prior to allo-HSCT (intensive chemotherapy, HR 2.05, 95% CI 1.13-3.71, P = 0.018) had a significantly negative impact on TRM. There was no significant difference of causes of death among the three groups (supplemental Table 7 ).
Discussion
The primary objective of this retrospective study was to evaluate the prognostic impact of the loss of chromosome 7q on the post-transplant outcomes of MDS patients. Previous studies analyzed the prognostic impact of the loss of 7q regardless of additional cytogenetic abnormalities: 
The multivariate analysis including the cytogenetic group as a covariate identified other significant factors as follows: a Other factors associated with worse OS were recipient age at transplantation (≥60 year), performance status (PS) at transplantation (PS 1-4 and missing data), the type of donor source (unrelated cord blood), and the interval from diagnosis to transplantation (>7.8 months)
b
Other factors associated with worse TRM were recipient age at transplantation (≥60 year), the type of donor source (HLA-mismatched related graft, unrelated bone marrow, and unrelated cord blood), and the interval from diagnosis to transplantation (>7.8 months); another factor associated with better TRM was the period of transplantation (2004-2008 and 2009-2012) c Other factors associated with an increased relapse rate were PS at transplantation (PS 1-4), the use of ATG in the conditioning regimen (presence), the type of GVHD prophylaxis (other than calcineurin inhibitor-based), and type of donor source (unrelated cord blood); another factor associated with a reduced relapse rate was the type of donor source (unrelated bone marrow) patients having isolated abnormality of der(1;7) (at most, n = 45) and −7/del(7q) (at most, n = 45) [12] [13] [14] [15] . Because these studies included the majority of non-transplant patients, to the best of our knowledge, the present study examined the largest number of post-transplant patients with der(1;7) or −7/del(7q) as the sole cytogenetic abnormality. Namely, the cohort of this study enabled a better estimation of the true prognostic impact of der(1;7) and −7/del(7q) on post-transplant outcomes. The ratios of der(1;7) (n = 94, 8.9%) and −7/del(7q) groups (n = 104, 9.8%) to NK group (n = 858, 81.3%) in our cohort were higher than those in the previous studies [16, 30] . Physician and patient willingness to consider the indication of allo-HSCT for these cytogenetic groups was reflected, at least in a part, the different distribution in our study. Another explanation for the different distribution was that der(1;7) was more frequent in Japanese than Caucasians as previously reported [30] .
One of the main questions in the present study was the prognostic impact of der(1;7) after allo-HSCT. In the original IPSS [2] , the loss of 7q was assigned as a poor prognosis factor, and der(1;7) was considered to be a more unfavorable indicator than NK. This resulted in the selection of aggressive therapeutic strategies for der(1;7)(q10; p10) group, including disease-altering treatments (i.e. DNA hypomethylating agents, intensive chemotherapy, and allo-HSCT) [13] . However, it currently remains unclear whether der(1;7) exhibits a survival disadvantage over NK due to the lack of any direct comparisons between der(1;7) and NK in MDS patients. It is important to note that we did not observe any differences in post-transplant outcomes between der(1;7) and NK groups with early and advanced disease status. One possible interpretation of these results is that der(1;7) did not have a prognostic impact in MDS patients after allo-HSCT.
Another interesting result of the present study was that der(1;7) group showed a lower CIR than −7/del(7q) group among the patients with advanced disease status, suggesting that der(1;7) group would benefit from allo-HSCT more than −7/del(7q) groups. The recent studies revealed that MDS patients with der(1;7) had the distinct clinical and pathological features, including ethnical differences and mutation profile [30, 31] . However, it is controversial whether der(1;7) abnormality defines a separate prognostic group in the previous studies involved both transplant and non-transplant patients [12, 13, 15] . In terms of prognostic value of der(1;7) group, our findings provided the clearer insights into clinical outcomes in MDS patients with der (1;7) who undergo allo-HSCT. The important result was that the impact of −7/del(7q) differed by disease status; it correlated with worse OS and higher CIR with advanced disease status, but not early disease status. In other words, −7/del(7q) exhibited different influences on post-transplant outcomes by the trajectory of the bone marrow blast percentage from the initial diagnosis to the time of transplantation. Since MDS patients with −7/del(7q) were more likely to progress to advanced disease status [12] , a bridging strategy using DNA hypomethylating agents and/or chemotherapy prior to allo-HSCT is warranted for these patients [32] [33] [34] . In this regard, the detection of somatic mutations related to disease progression may be useful for making better decisions on how to treat the −7/del(7q) group [35] .
Among patients with advanced disease status, CIR was significantly higher in −7/del(7q) group than in NK group. This may have been partly due to the larger burden of residual tumor cells after allo-HSCT in −7/del(7q) group than in NK group. Thus, the monitoring of minimal residual disease may be helpful for −7/del(7q) using novel molecular-based approaches (e.g. a digital polymerase chain reaction [PCR] method and next-generation sequencing), multiparameter flow cytometry, and WT1 expression levels with PCR [36] [37] [38] . These approaches may help to employ and optimize post-transplant therapy, such as the introduction of DNA hypomethylating agents, other compounds, and donor lymphocyte infusion as pre-emptive strategies to prevent the future relapse of MDS [39] [40] [41] [42] [43] [44] [45] .
It was interesting to note that conditioning regimenrelated factors correlated with increased CIR. The use of ATG in the conditioning regimen for patients with advanced disease status and non-myeloablative conditioning regimen for those with early disease status were significant factors for a significantly higher CIR and were independent from the cytogenetic group. Previous studies indicated that the graft-versus-leukemia effect and optimal intensity of the conditioning regimen were crucial for the long-term survival of MDS patients [26, [46] [47] [48] [49] [50] . These findings suggested that careful attention to the conditioning regimen in consideration of the disease status at transplantation is needed for patients with single der(1;7) or −7/del (7q) abnormality and NK.
We were unable to assess the impact of somatic mutations due to the lack of data in TRUMP. Previous studies showed that the distinct mutation spectrum was identified in each karyotype; MDS patients with der(1;7) more often had RUNX1 gene mutations [12, 31] , whereas those with −7/del (7q) had the mutations in SAMD9, SAMD9L, EZH2, MLL3, and TP53 genes [51, 52] . Yoshizato et al. suggested that high-risk cytogenetic abnormalities, including complex karyotype and chromosome 7 abnormality as well as the somatic mutations were independent risk factors for patients with MDS transplanted using unrelated bone marrow or peripheral blood stem cell [53] . The combination of TP53 mutation and complex karyotype was reported to strongly affect the post-transplant outcome [53, 54] ; however, the combinations of each somatic mutation and chromosome 7 abnormality were not fully understood. Since it has been reported that several somatic mutations (i.e. RUNX1 and TP53 genes) and chromosomal abnormalities (i.e. chromosome 7 abnormality and trisomy 1q) negatively affected post-transplant outcomes [53] [54] [55] , further attempts are necessary combining cytogenetics, molecular genetics, and Other factors associated with worse TRM were the type of donor source (HLA-mismatched related graft and unrelated cord blood) and type of disease-altering therapy prior to allo-HSCT (intensive chemotherapy alone) c Other factors associated with an increased relapse rate were recipient age at transplantation (50-59 years) and the intensity of the conditioning regimen (non-myeloablative conditioning regimen); other factors associated with a reduced relapse rate were the type of donor source (HLA-mismatched related graft and unrelated bone marrow) and period of transplantation (2004) (2005) (2006) (2007) (2008) pathological data to generate a better prognostic system for transplant candidates having the loss of chromosome 7q. In addition, the sequencing-based monitoring for measurable residual disease was reported to be helpful for predicting disease progression after allo-HSCT [56] , which could support the decision to promptly initiate pre-emptive and salvage treatment. This could be also applied to MDS patients with der(1;7) or −7/del(7q) abnormality [31, 51, 52, 57] . There were several limitations in the present study. We were unable to evaluate the impact of IPSS, revised IPSS, and karyotype, including additional cytogenetic abnormalities, before allo-HSCT on post-transplant outcome [58] [59] [60] . Considering these predictive values for post-transplant outcomes, it would be of interest to determine whether these factors are helpful for risk-stratification among der (1;7) or −7/del(7q) groups. Furthermore, we carefully assessed the eligibility of patients who met all inclusion and exclusion criteria; however, patient characteristics and transplant procedures were heterogeneous. These factors may have exerted a bias and potentially affected the results obtained. Therefore, these results need to be cautiously interpreted and confirmed in larger prospective studies.
In conclusion, the present study showed that allo-HSCT may provide durable remission for MDS patients with the loss of chromosome 7q, whereas its impact on OS and CIR after transplantation may differ based on the type of loss of 7q. The present results may contribute to improving the management of MDS patients with the loss of chromosome 7q before and after transplantation.
